Crossmark

Microbiological risk factors, ICU survival, and 1-year survival in hematological patients with pneumonia requiring invasive mechanical ventilation

Published Online: 2024-06-26

Published Print: 2024-09

Authors

Seybold, Benjamin https://orcid.org/0009-0003-6110-2713
Funk, Timo

Dreger, Peter

Egerer, Gerlinde

Brandt, Juliane

Mueller-Tidow, Carsten

Giesen, Nicola

Merle, Uta
Funding

Funding for this research was provided by:

Universitätsklinikum Heidelberg
License Information

Text and Data Mining valid from 2024-06-26

Version of Record valid from 2024-06-26
More Information

Article History

Received: 28 January 2024

Accepted: 19 June 2024

First Online: 26 June 2024

Declarations

:

: NG reports honoraria from AbbVie, AstraZeneca, GSK, Hexal, MSD, travel grants from Janssen and participation on an advisory board to AstraZeneca. JB reports participation on an advisory board to Gilead. BS, TF, PD, GE, CMT and UM report no competing interests.

Document is current